iRadimed Corporation Announces Quarterly Dividend of $0.20 (NASDAQ:IRMD)

iRadimed Corporation (NASDAQ:IRMD) declared a quarterly dividend on Friday, July 31st. Stockholders of record on Friday, August 14th will be given a dividend of 0.20 per share by the medical equipment provider on Friday, August 28th. This represents a c) dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, August 14th.

iRadimed has a dividend payout ratio of 40.2% indicating that its dividend is sufficiently covered by earnings.

iRadimed Stock Down 4.6%

Shares of NASDAQ:IRMD opened at $90.86 on Friday. The business’s 50 day moving average is $94.54 and its 200 day moving average is $95.70. iRadimed has a 12-month low of $57.83 and a 12-month high of $107.90. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of 49.65 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The business had revenue of $20.47 million during the quarter, compared to analyst estimates of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, equities research analysts expect that iRadimed will post 1.52 earnings per share for the current year.

Key Headlines Impacting iRadimed

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
• Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
• Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.